List of Otovel drug patents
Otovel is owned by Laboratorios Salvat.
Otovel contains Ciprofloxacin Hydrochloride; Fluocinolone Acetonide.
Otovel has a total of 1 drug patent out of which 0 drug patents have expired.
Otovel was authorised for market use on 29 April, 2016.
Otovel is available in solution/drops;otic dosage forms.
Otovel can be used as treatment of acute otitis media.
The generics of Otovel are possible to be released after 24 March, 2030.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8932610 | LABORATORIOS SALVAT | Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation |
Mar, 2030
(7 years from now) | |
Drugs and Companies using CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE ingredient
Market Authorisation Date: 29 April, 2016
Treatment: Treatment of acute otitis media
Dosage: SOLUTION/DROPS;OTIC
OTOVEL family patents
2
European Union
1
Korea, Republic of
1
Hong Kong
1
Poland
1
United States
1
Australia
1
Russia
1
Canada
1
Denmark
1
Argentina
1
Mexico
1
Spain
1
Japan
1
China
1
Brazil
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic